Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.86 |
| ▸ | RAF1 | P04049 | 15/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.86 |
| ▸ | BRAF | P15056 | 1/20 | 0.86 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.86 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.46 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959646 | 0.93 | MAP2K1 (0.86) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL960093 | 0.92 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL29515377 | 0.92 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL29358292 | 0.92 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| SCHEMBL26997846 | 0.92 | MAP2K1 (0.84) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL29360048 | 0.92 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL963841 | 0.92 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL959677 | 0.92 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL963844 | 0.92 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL959675 | 0.92 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873296-B2 | Solid forms of a dual RAF/MEK inhibitor | VERASTEM, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230277535-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873296-B2 | Solid forms of a dual RAF/MEK inhibitor | BRAF, RAF1, NRAS | MAP2K1 5/4885RAF1 2/4885CYP2C9 872/4885 |
| US-20230277535-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | BRAF, PTK2, NRAS | MAP2K1 6/4885RAF1 8/4885CYP2C9 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.